Absorption, metabolism, and excretion of [¹⁴C]evogliptin tartrate in male rats and dogs

References

• Cahn, A., S. Cernea, and I. Raz. 2016. An update on DPP-4 inhibitors in the management of type 2 diabetes. Expert Opinion Emerging Drugs 21:409–19. doi:10.1080/14728214.2016.1257608.
   PubMed Web of Science ®Google Scholar
• Chae, Y.-N., T.-H. Kim, M.-K. Kim, C.-Y. Shin, I.-H. Jung, Y. S. Sohn, and M.-H. Son. 2015. Beneficial effects of evogliptin, a novel dipeptidyl peptidase 4 inhibitor, on adiposity with increased Ppargc1a in white adipose tissue in obese mice. Plos One 10:e0144064. doi:10.1371/journal.pone.0144064.
   PubMed Web of Science ®Google Scholar
• Cho, J. M., H. W. Jang, H. Cheon, Y. T. Jeong, D.-H. Kim, Y.-M. Lim, S.-H. Choi, E.-K. Yang, C.-Y. Shin, M. H. Son, S. H. Kim, et al. 2011. A novel dipeptidyl peptidase IV inhibitor DA-1229 ameliorates streptozotocin-induced diabetes by increasing β-cell replication and neogenesis. Diabetes Research and Clinical Practice 91:72–79. doi:10.1016/j.diabres.2010.10.012.
   PubMed Web of Science ®Google Scholar
• Deacon, C. F., and H. E. Lebovitz. 2016. Comparative review of dipeptidyl peptidase-4 inhibitors and sulphonylureas. Diabetes Obesity Metabolic 18:333–47. doi:10.1111/dom.12610.
   PubMed Web of Science ®Google Scholar
• Diamond, G. L., N. P. Skoulis, A. R. Jeffcoat, and J. F. Nash. 2017. A physiologically based pharmacokinetic model for the broad-spectrum antimicrobial zinc pyrithione: I. Development and verification. Journal Toxicogical Environment Health A 80:69–90. doi:10.1080/15287394.2016.1245123.
   PubMed Web of Science ®Google Scholar
• Gu, N., M. K. Park, T.-E. Kim, M. Y. Bahng, K. S. Lim, S.-H. Cho, S. H. Yoon, J.-Y. Cho, I.-J. Jang, and K.-S. Yu. 2014. Multiple-dose pharmacokinetics and pharmacodynamics of evogliptin (DA-1229), a novel dipeptidyl peptidase IV inhibitor, in healthy volunteers. Drug Design Developments Therapeutics 8:1709–21. doi:10.2147/DDDT.S65678.
   PubMed Web of Science ®Google Scholar
• Hong, S.-M., C.-Y. Park, D.-M. Hwang, K. A. Han, C. B. Lee, C. H. Chung, K.-H. Yoon, J.-O. Mok, K. S. Park, and S.-W. Park. 2017. Efficacy and safety of adding evogliptin versus sitagliptin for metformin-treated patients with type 2 diabetes: A 24-week randomized, controlled trial with open label extension. Diabetes Obesity Metabolic 19:654–63. doi:10.1111/dom.12870.
   PubMed Web of Science ®Google Scholar
• Jeong, H.-U., J.-H. Kim, D. Lee, H. Shim, and H. S. Lee. 2015. In vitro metabolic pathways of the new anti-diabetic drug evogliptin in human liver preparations. Molecules (Basel, Switzerland) 20:19808. doi:10.3390/molecules201219808.
   Web of Science ®Google Scholar
• Johnson, C. H., O. Slanar, K. W. Krausz, D. W. Kang, A. D. Atterson, J. H. Kim, H. Luecke, F. J. Gonzalez, and J. R. Idle. 2012. Novel metabolites and roles for alpha-tocopherol in humans and mice discovered by mass spectrometry-based metabolomics. American Journal Clinical Nutritional 96:818–30. doi:10.3945/ajcn.112.042929.
   PubMed Web of Science ®Google Scholar
• Jung, C. H., C.-Y. Park, K.-J. Ahn, N.-H. Kim, H.-C. Jang, M.-K. Lee, J.-Y. Park, C.-H. Chung, K.-W. Min, Y.-A. Sung, et al. 2015. A randomized, double-blind, placebo-controlled, phase II clinical trial to investigate the efficacy and safety of oral DA-1229 in patients with type 2 diabetes mellitus who have inadequate glycaemic control with diet and exercise. Diabetes/Metabolism Research and Reviews 31:295–306. doi:10.1002/dmrr.2613.
   PubMed Web of Science ®Google Scholar
• Kim, H. J., W. Y. Kwak, J. P. Min, J. Y. Lee, T. H. Yoon, H. D. Kim, C. Y. Shin, M. K. Kim, S. H. Choi, H. S. Kim, et al. 2011. Discovery of DA-1229: A potent, long acting dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes. Bioorganic Medica Chemical Letters 21:3809–12. doi:10.1016/j.bmcl.2011.04.029.
   PubMed Web of Science ®Google Scholar
• Kim, M.-K., Y. N. Chae, G.-J. Ahn, C. Y. Shin, S.-H. Choi, E. K. Yang, Y. S. Sohn, and M. H. Son. 2017. Prevention and treatment effect of evogliptin on hepatic steatosis in high-fat-fed animal models. Archives of Pharmacal Research 40:268–81. doi:10.1007/s12272-016-0864-z.
   PubMed Web of Science ®Google Scholar
• Kim, M.-K., Y. N. Chae, H. D. Kim, E. K. Yang, E. J. Cho, S.-H. Choi, Y.-H. Cheong, H.-S. Kim, H. J. Kim, Y. W. Jo, et al. 2012. DA-1229, a novel and potent DPP4 inhibitor, improves insulin resistance and delays the onset of diabetes. Life Sciences 90:21–29. doi:10.1016/j.lfs.2011.10.007.
   PubMed Web of Science ®Google Scholar
• Kim, T.-H., M.-K. Kim, Y.-H. Cheong, Y.-N. Chae, Y. Lee, S.-O. Ka, I.-H. Jung, C.-Y. Shin, E. J. Bae, and M.-H. Son. 2016. Hepatic role in an early glucose-lowering effect by a novel dipeptidyl peptidase 4 inhibitor, evogliptin, in a rodent model of type 2 diabetes. European Journal Pharmacology 771:65–76. doi:10.1016/j.ejphar.2015.11.029.
   PubMed Web of Science ®Google Scholar
• Lee, H. K., M.-K. Kim, H. D. Kim, H. J. Kim, J. W. Kim, J.-O. Lee, C.-W. Kim, and E. K. Kim. 2017. Unique binding mode of Evogliptin with human dipeptidyl peptidase IV. Biochemical Biophysics Researcher Communicable 494:452–59. doi:10.1016/j.bbrc.2017.10.101.
   PubMed Web of Science ®Google Scholar
• Louis, G. W., D. R. Hallinger, M. J. Braxton, A. Kamel, and T. E. Stoker. 2017. Effects of chronic exposure to triclosan on reproductive and thyroid endpoints in the adult Wistar female rat. Journal Toxicogical Environment Health A 80:236–49. doi:10.1080/15287394.2017.1287029.
   PubMed Web of Science ®Google Scholar
• Luo, Y.-S., J. A. Cichocki, T. J. McDonald, and I. Rusyn. 2017. Simultaneous detection of the tetrachloroethylene metabolites S-(1,2,2-trichlorovinyl) glutathione, S-(1,2,2-trichlorovinyl)-L-cysteine, and N-acetyl-S-(1,2,2-trichlorovinyl)-L-cysteine in multiple mouse tissues via ultra-high performance liquid chromatography electrospray ionization tandem mass spectrometry. Journal Toxicogical Environment Health A 80:513–24. doi:10.1080/15287394.2017.1330585.
   PubMed Web of Science ®Google Scholar
• Luo, Y.-S., S. Furuya, W. Chiu, and I. Rusyn. 2018. Characterization of inter-tissue and inter-strain variability of TCE glutathione conjugation metabolites DCVG, DCVC, and NAcDCVC in the mouse. Journal Toxicogical Environment Health A 81:37–52. doi:10.1080/15287394.2017.1408512.
   PubMed Web of Science ®Google Scholar
• Oh, E. S., C. Choi, C. O. Kim, K. H. Kim, Y. N. Kim, S. J. Kim, and M. S. Park. 2017a. Effects of clarithromycin on the pharmacokinetics of evogliptin in healthy volunteers. Journal Clinical Pharmacology Therapeutics 42:689–94. doi:10.1111/jcpt.12604.
   PubMed Web of Science ®Google Scholar
• Oh, J., A. H. Kim, S. Lee, H. Cho, Y. S. Kim, M. Y. Bahng, S. H. Yoon, J.-Y. Cho, I.-J. Jang, and K.-S. Yu. 2017b. Effects of renal impairment on the pharmacokinetics and pharmacodynamics of a novel dipeptidyl peptidase-4 inhibitor, evogliptin (DA-1229). Diabetes Obesity Metabolic 19:294–98. doi:10.1111/dom.12813.
   PubMed Web of Science ®Google Scholar
• Park, J., S. W. Park, K. H. Yoon, S. R. Kim, K. J. Ahn, J. H. Lee, J. O. Mok, C. H. Chung, K. A. Han, G. P. Koh, et al. 2017. Efficacy and safety of evogliptin monotherapy in patients with type 2 diabetes and moderately elevated glycated haemoglobin levels after diet and exercise. Diabetes Obesity Metabolic 19:1681–87. doi:10.1111/dom.12987.
   PubMed Web of Science ®Google Scholar
• Rhee, S.-J., Y. J. Choi, S. H. Lee, J. Oh, S.-J. Kim, S. H. Yoon, J.-Y. Cho, and K.-S. Yu. 2016a. Pharmacokinetic and pharmacodynamic interactions between metformin and a novel dipeptidyl peptidase-4 inhibitor, evogliptin, in healthy subjects. Drug Design Developments Therapeutics 10:2525–34. doi:10.2147/DDDT.S110712.
   PubMed Web of Science ®Google Scholar
• Rhee, S.-J., S. H. Lee, S. H. Yoon, J.-Y. Cho, I.-J. Jang, and K.-S. Yu. 2016b. Pharmacokinetics of the evogliptin/metformin extended-release (5/1,000 mg) fixed-dose combination formulation compared to the corresponding loose combination, and food effect in healthy subjects. Drug Design Developments Therapeutics 10:1411–18. doi:10.2147/DDDT.S102459.
   PubMed Web of Science ®Google Scholar
• Roselli, C., D. Desideri, C. Cantaluppi, F. Ceccotto, L. Feduzi, and M. A. Meli. 2017. Radioactivity measurements and dosimetric evaluation in meat of wild birds. Journal Toxicogical Environment Health A 80:374–81. doi:10.1080/15287394.2017.1329103.
   PubMed Web of Science ®Google Scholar
• Tan, X., and J. Hu. 2016. Evogliptin: A new dipeptidyl peptidase inhibitor for the treatment of type 2 diabetes. Expert Opinion Pharmacotherapy 17:1285–93. doi:10.1080/14656566.2016.1183645.
   PubMed Web of Science ®Google Scholar
• Yoon, S., S. J. Rhee, S. I. Park, S. H. Yoon, J.-Y. Cho, I.-J. Jang, S. Lee, and K.-S. Yu. 2017. Pharmacokinetic comparison using two tablets of an evogliptin/metformin XR 2.5/500 mg fixed dose combination vs. 1 tablet each of evogliptin 5 mg and metformin XR 1,000 mg. International Journal Clinical Pharmacology Therapeutics 55:533–39. doi:10.5414/cp202930.
   PubMed Web of Science ®Google Scholar